


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

in which:

X is C<sub>1-6</sub>alkyl or OR<sup>6</sup>;

Y is selected from hydrogen, halogen, CN, nitro, SO<sub>2</sub>R<sup>3</sup>, OR<sup>4</sup>, SR<sup>4</sup>, SOR<sup>3</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, CONR<sup>4</sup>R<sup>5</sup>, NR<sup>4</sup>R<sup>5</sup>, NR<sup>6</sup>SO<sub>2</sub>R<sup>3</sup>, NR<sup>6</sup>CO<sub>2</sub>R<sup>6</sup>, NR<sup>6</sup>COR<sup>3</sup>, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, OR<sup>6</sup> and NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup>; where n is 0, 1 or 2;

Z is aryl or a ring A, where A is a six membered heterocyclic aromatic ring containing one or more nitrogen atoms or may be a 6,6 or 6,5 fused bicyclic containing one or more O, N, S atoms, the aryl or A rings all being optionally substituted by one or more substituents independently selected from from hydrogen, halogen, CN, OH, SH, nitro, COR<sup>9</sup>, CO<sub>2</sub>R<sup>6</sup>, SO<sub>2</sub>R<sup>9</sup>, OR<sup>9</sup>, SR<sup>9</sup>, SOR<sup>9</sup>, SO<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, CONR<sup>10</sup>R<sup>11</sup>, NR<sup>10</sup>R<sup>11</sup>, NHSO<sub>2</sub>R<sup>9</sup>, NR<sup>9</sup>SO<sub>2</sub>R<sup>9</sup>, NR<sup>6</sup>CO<sub>2</sub>R<sup>6</sup>, NHCOR<sup>9</sup>, NR<sup>9</sup>COR<sup>9</sup>, NR<sup>6</sup>CONR<sup>4</sup>R<sup>5</sup>, NR<sup>6</sup>SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, aryl, heteroaryl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, OR<sup>6</sup>, NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup> (~~where n is 0, 1 or 2~~), CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>.

R<sup>1</sup> and R<sup>2</sup> independently represent a hydrogen atom, halogen, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or a C<sub>1-6</sub>alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, NR<sup>6</sup>R<sup>7</sup>, OR<sup>6</sup>, S(O)<sub>n</sub>R<sup>6</sup> (~~where n is 0, 1 or 2~~);

or

R<sup>1</sup> and R<sup>2</sup> together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR<sup>6</sup> and itself optionally substituted by one or more C<sub>1</sub>-C<sub>3</sub> alkyl or halogen;

R<sup>3</sup> represents C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl which may be optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, OR<sup>6</sup> and NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup> (~~where n = 0,1 or 2~~), CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>;

R<sup>4</sup> and R<sup>5</sup> independently represent hydrogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen,

C<sub>3</sub>-C<sub>7</sub> cycloalkyl, OR<sup>6</sup> and NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup> (where n = 0, 1 or 2), CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>;

or

R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)<sub>n</sub> (where n = 0, 1 or 2), NR<sup>8</sup>, and itself optionally substituted by halogen or C<sub>1-3</sub> alkyl;

R<sup>6</sup> and R<sup>7</sup> independently represents a hydrogen atom or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> is hydrogen, C<sub>1-4</sub> alkyl, -CO-C<sub>1</sub>-C<sub>4</sub> alkyl, CO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub> alkyl or CONR<sup>6</sup>C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>9</sup> represents aryl, heteroaryl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub> alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, aryl, heteroaryl OR<sup>6</sup> and NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup> (where n = 0, 1 or 2), CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>;

R<sup>10</sup> and R<sup>11</sup> independently represent aryl or heteroaryl, hydrogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub> alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, aryl, heteroaryl, OR<sup>6</sup> and NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup> (where n = 0, 1 or 2), CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>;

or

$R^{10}$  and  $R^{11}$  together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O,  $S(O)_n$  (~~where n = 0, 1 or 2~~),  $NR^8$ , and itself optionally substituted by halogen or  $C_1$ - $C_3$  alkyl.

2. (Currently amended) A compound according to claim 1 in which  $R^1$  and  $R^2$  independently represent a hydrogen atom,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_7$  cycloalkyl or a  $C_{1-6}$ alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen,  $C_3$ - $C_7$  cycloalkyl,  $NR^6R^7$ ,  $OR^6$ ,  $S(O)_nR^6$  (~~where n is 0, 1 or 2~~) or  $R^1$  and  $R^2$  together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S,  $NR^6$  and itself optionally substituted by one or more  $C_1$ - $C_3$  alkyl or halogen;
3. (Currently amended) A compound according to claim 1 [[or 2]] in which X is  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy.
4. (Currently amended) A compound according to claim 1-any one of claims 1 to 3 in which Y is hydrogen.
5. (Currently amended) A compound according to claim 1-any one of claims 1 to 4 in which Z is phenyl or optionally substituted as defined in claim 1.
6. (Currently amended) A compound according to claim 1-any one of claims 1 to 4 in which Z is phenyl or optionally substituted by one or more substituents independently selected from halogen,  $C_{1-3}$ alkyl, cyano and  $SO_2R^9$ .
7. (Currently amended) A compound according to claim 1-any one of claims 1 to 6 in which  $R^1$  and  $R^2$  are both hydrogen or one is hydrogen and the other is  $C_{1-3}$  alkyl.

8. (Currently amended) A compound according to claim 1-any one of claims 1 to 7 selected from:

[(5-Methylbiphenyl-2-yl)oxy]acetic acid,  
{[5-Ethyl-4'-(methylsulfonyl)biphenyl-2-yl]oxy}acetic acid,  
{[4'-(Ethylsulfonyl)-5-methoxybiphenyl-2-yl]oxy}acetic acid,  
[[4-Chloro-4'-(ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,  
[[4'-(Ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,  
2-[[3'-Cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,  
2-[[2'-Fluoro-5'-cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,  
and pharmaceutically acceptable salts thereof.

9. (Cancelled)

10. (Currently amended) A method of treating a disease mediated by prostaglandin D2, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claim 1-claims 1 to 8.

11. (Currently amended) A method of treating a respiratory disease, ~~such as asthma and rhinitis~~, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as defined in claim 1-claims 1 to 8.

12. (New) The method of claim 11, wherein the respiratory disease is asthma or rhinitis.

13. (New) A compound according to claim 2 in which X is C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkoxy.

14. (New) A compound according to claim 2 in which Y is hydrogen.

15. (New) A compound according to claim 2 in which Z is phenyl or optionally substituted as defined in claim 1.

16. (New) A compound according to claim 2 in which Z is phenyl or optionally substituted by one or more substituents independently selected from halogen, C<sub>1-3</sub>alkyl, cyano and SO<sub>2</sub>R<sup>9</sup>.

17. (New) A compound according to claim 2 in which R<sup>1</sup> and R<sup>2</sup> are both hydrogen or one is hydrogen and the other is C<sub>1-3</sub>alkyl.